An analysis of the relationship between different autoantibodies and clinical findings in a group of Turkish patients with systemic lupus erythematosus

Gazi Medical Journal

Volumn 19, Issue 3, 2008, Pages 126-132

  Altintaş, N Defne ^a,c   Tiryaki, A Olcay ^b   Tutkak, Hüseyin ^b   Düzgün, Nurşen ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Anti 2 glycoprotein 1; Anti Clq; Anticardiolipin antibodies; Nephritis; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RAYNAUD PHENOMENON; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 60749132783     PISSN: 1300056X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Edworthy SM. Clinical manifestations of systemic lupus erythematosus. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology, Philadelphia: W. B. Saunders, 2001; 1105-1124.
2. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine 1993; 72: 113-124.
3. Frontiers of SLE: Review of the 5th international congress on SLE, Cancun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999; 29: 112-130.
4. Swaak AJG, Brink HG, Smeenk RJT, et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology 1999; 38: 953-958.
5. Berden JHM. Lupus nephritis. Kidney Int 1997; 52: 538-558.
6. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504-1511.
7. Siegert C, Daha M, Westedt ML, et al. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and ds-DNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230-234.
8. Siegert CEH, Kazatchkine MD, Sjöholm A, et al. Autoantibodies against C1q: view on clinical relevance and pathogenic roles. Clin Exp Immunol 1999; 116: 4-8.
9. Gunnarsson I, Sundelin B, Heimbürger M, et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693-9.
10. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214.
11. Inanç M, Radway-Bright EL, Isenberg DA. β2-glycoprotein I and anti-β2-glycoprotein 1 antibodies: Where are we now? Br J Rheumatol 1997; 36: 1247-1257.
12. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424-1429.
13. Davies ML, Young SP, Welsh K, et al. Immune responses to native β2-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Rheumatology 2002; 41: 395-400.
14. Visvanathan S, McNeil HP. Cellular immunity to β2-glycoprotein I in patients with the antiphospholipid syndrome. J Immunol 1999; 162: 6919-6925.
15. Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-β2-glycoprotein I antibodies in a large series of European Patients with Systemic Lupus Erythematosus. Scand J Rheumatol 1999; 28:344-351.
16. Frampton G, Hicks J, Cameron JS. Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39: 1125-1231.
17. Loizou S, Samarkos M, Morsworthy PJ, et al. Significance of anticardiolipin and anti-β2-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000; 39: 962-968.
18. Wakai S, Matsumura O, Koike T, et al. Anticardiolipin antibody and renal microthrombi in lupus nephritis. Ryumachi 1991; 5: 481-487.
19. Tubach F, Hayem G, Marchand JL, et al. IgG anti-β2-glycoprotein 1 antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27: 1437-1443.
20. De Bandt M, Benali K, Guillevin L, et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999; 26: 91-96.
21. Moroni G, Trendelenburg M, Del Papa N, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-498.
22. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
23. Bombardier C, Dladman DD, Urowitz MB, et al. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
24. Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum 1991; 34: 937-944.
25. Cortes-Hernandez J, Ordi-Ros J, Labrador M, et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am J Med 2004; 116: 165-173.
26. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β2-glycoprotein and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466-1474.
27. Alarcon-Segovia D, Mestanza M, Cabiedes J, et al. The antiphospholipid/ cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to β2-glycoprotein I but no antibodies to detectable in standart anti-phospholipid assays. J Rheumatol 1997; 24: 1545-1551.
28. Keane PA, Ravikumar K, O'Shea SI, et al. Anti-β2-glycoprotein I and the anti-phospolipid syndrome. Am J Ophthalmol 2006; 142: 701-702.
29. Cabiedes J, Cabral AR, Alarcion-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
30. Bruce IN, Soloninka CAC, Spitzer K, et al. Prevalence of antibodies to β2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid syndrome criteria: a single center study and literature review. J Rheumatol 2000; 27: 2833-2837.
31. Inanç M, Donohoe S, Ravirajan CT, et al. Anti-β2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998; 37: 1089-1094.
32. Voss A, Jacobsen S, Heegard NHH. Association of β2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus 2001; 10: 533-538.
33. Audrain MAP, El Kouri D, Hamidou MA, et al. Value of autoantibodies to β2-glycoprotein I in the diagnosis of antiphospholipid syndrome. Rheumatology 2002; 41: 550-553.
34. Perez-Vazquez ME, Villa AR, Drenkard C, et al. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 437-442.
35. Bertolaccani ML, Atsumi T, Contreras AE, et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001; 28: 2637-2643.
36. Gunnarson I, Rönnelid J, Huang YH, et al. Association between ongoing Anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997; 36: 32-37.
37. Norsworthy P, Theodoridis E, Botto M, et al. Overrepresentation of the FCβ receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 1999; 42: 1828-1832.
38. Gunnarsson I, Rönnelid J, Lundberg I, et al. Occurrence of anti-C1q antibodies in IgA nephropathy. Nephrol Dial Transplant 1997; 12: 2263-2268.
39. Trendelenburg M, Marfurt J, Gerber I, et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1998; 42: 187-188.
40. Kumar A, Gupta R, Varghese T, et al. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian J Med Res 1999; 110: 190-193.
41. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 2004; 13: 290-297.
42. Siegert CEH, Daha MR, Halma C, et al. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992; 10: 19-23.
43. Huong DLT, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. Medicine 1999; 78: 148-166.
44. Foster MH, Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol 1999; 19: 173-181.
45. Fofi C, Cuadrado MJ, Godfrey T, et al. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin Exp Rheumatol 2001; 19: 75-77.
46. Sahin M, Duzgun N, Tunc SE, Tutkak H. Antibodies to beta2-glycoprotein-I: relation of anticardiolipin antibodies with clinical and laboratory parameters in patients with systemic lupus erythematosus. Clin Biochem 2007; 40: 526-530.